SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

NCT00361244 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Colorectal Carcinoma

Interventions

DRUG: SU011248
DRUG: Irinotecan
DRUG: Cetuximab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]